Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3BCHECHRM1CHRM2CHRM3CHRM4CHRNA3CHRNA4CHRNB2CHRNB4ESR1ESR2GABRA1GABRB1GABRG2GBA1GHSRHRH1HTR1DHTR2AMAOBOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8UGCGrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 5/20 | 0.40 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL8995624 | 0.96 | CA4 (0.47) | TSHRLMNACA4FAHD1BLM | |
| Cadaverine Tartrate SCHEMBL29077067 | 0.96 | CA4 (0.47) | TSHRLMNACA4FAHD1BLM | |
| Cadaverine Tartrate SCHEMBL29409197 | 0.96 | TSHR (0.47) | TSHRLMNACA4FAHD1BLM | |
| Cadaverine Tartrate SCHEMBL80796 | 0.96 | TSHR (0.47) | TSHRLMNACA4FAHD1BLM | |
| Cadaverine Tartrate SCHEMBL29499522 | 0.96 | TSHR (0.47) | TSHRLMNACA4FAHD1BLM | |
| Cadaverine Tartrate SCHEMBL1438667 | 0.92 | TSHR (0.44) | TSHRLMNACA4FAHD1BLM | |
| Cadaverine Tartrate SCHEMBL11502416 | 0.92 | TSHR (0.44) | TSHRLMNACA4FAHD1BLM | |
| Cadaverine Tartrate SCHEMBL11525885 | 0.92 | TSHR (0.44) | TSHRLMNACA4FAHD1BLM | |
| Cadaverine Tartrate SCHEMBL330144 | 0.92 | TSHR (0.44) | TSHRLMNACA4FAHD1BLM | |
| Cadaverine Tartrate SCHEMBL1434088 | 0.92 | TSHR (0.44) | TSHRLMNACA4FAHD1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10251909-B2 | Potassium-magnesium citrate as a surrogate of the DASH diet in managing hypertension | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-04-09 | — | — | US | disclosed |
| US-20080193525-A1 | A mixture of potassium citrate and magnesium citrate; antidiabetic agents, diuretics, metabolic disorders; uric acid and calcium stones, hypokalemia, hypomagnesemia; side effect reduction | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-08-14 | — | — | US | disclosed |